Immunophotonics, Inc., in collaboration with Dr. Robert CG Martin II, M.D, PhD, FACS, who serves as the Principal Investigator and National Coordinating Investigator at the University of Louisville School of Medicine, Division of Surgical Oncology in Louisville KY, announced that the first patient has been dosed in a randomised, phase 2 study, IIO-824 / INJECTABL-2.